Pixnio

Pfizer/BioNTech vaccine protects children against rare COVID-19 complication

Two doses of the Pfizer Inc (PFE.N) and BioNTech (22UAy.DE) COVID-19 vaccine are highly protective against a rare but often serious condition in children that causes organ inflammation weeks after COVID-19 infections, a U.S. Centers for Disease Control and Prevention report said on Friday.

The vaccine was estimated to be 91% effective in preventing Multisystem Inflammatory Syndrome in Children (MIS-C) in 12- to 18-year-olds, the study said. MIS-C causes inflammation in children in organs including the heart, lungs, kidneys and brain two to six weeks after a mild or asymptomatic infection.

The estimate is based on the assessment of 283 hospitalized patients aged 12–18 years at 24 children’s hospitals in 20 states between July and early December, when the prevalence of the Delta coronavirus variant was high.

All 38 MIS-C patients requiring life support were unvaccinated, the study said.

Read Full Story
Reuters Rating

Share this:

Leave a Reply

%d bloggers like this: